Review of obesity pharmacotherapy effects on body composition examines how GLP-1 and related drugs affect muscle mass, fat distribution, and bone density during weight loss.
Key findingReview of obesity pharmacotherapy effects on body composition examines how GLP-1 and related drugs a
What the researchers found
Review of obesity pharmacotherapy effects on body composition examines how GLP-1 and related drugs affect muscle mass, fat distribution, and bone density during weight loss.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Review covers liraglutide, semaglutide, tirzepatide, and naltrexone/bupropion. Specific muscle preservation percentages not detailed in abstract.
How the study worked
In publication.
Who was studied
Adults with obesity using pharmacotherapy for weight loss
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
The effect of obesity pharmacotherapy on body composition, including muscle mass.
International journal of obesity (2005), 49(3), 381-387
Citation
Argyrakopoulou, Georgia; Gitsi, Evdoxia; Konstantinidou, Sofia K; Kokkinos, Alexander. (2025). The effect of obesity pharmacotherapy on body composition, including muscle mass.. International journal of obesity (2005), 49(3), 381-387. https://doi.org/10.1038/s41366-024-01533-3